Sarepta Therapeutics (SRPT) Net Income towards Common Stockholders (2010 - 2026)

Sarepta Therapeutics' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $331.0 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 173.96% year-over-year to $331.0 million; the TTM figure through Mar 2026 stood at $65.1 million (up 126.21% YoY), while the FY2025 annual figure was -$713.4 million, down 403.27% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $331.0 million, up from -$282.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $331.0 million in Q1 2026, with the low at -$516.8 million in Q1 2023.
• The 5-year median for Net Income towards Common Stockholders is -$23.9 million (2023), against an average of -$55.7 million.
• Peak annual rise in Net Income towards Common Stockholders reached 2796.15% in 2025, while the deepest fall reached 1324.47% in 2025.
• Sarepta Therapeutics' Net Income towards Common Stockholders stood at $329.3 million in 2022, then tumbled by 86.19% to $45.5 million in 2023, then surged by 249.09% to $158.8 million in 2024, then sank by 278.14% to -$282.9 million in 2025, then soared by 217.0% to $331.0 million in 2026.
• Business Quant data shows SRPT's Net Income towards Common Stockholders at $331.0 million in Q1 2026, -$282.9 million in Q4 2025, and -$179.9 million in Q3 2025.